Drug-Target Information
Drug Name Target Name Drug Type Target Type Source Drug MeSHID Interaction Score Drug Status Target Action
brentuximab vedotin tumor necrosis factor receptor superfamily member 8 biotech NA drugbank , DGIDB Lymphoma[MeSHID:D008223]
Ki-1+ Anaplastic Large Cell Lymphoma[MeSHID:D017728]
Hodgkin Disease[MeSHID:D006689]
Disruptive
Impulse Control
and Conduct Disorders[MeSHID:D007174]
NA approved,investigational binder,antibody
brentuximab vedotin tumor necrosis factor receptor superfamily member 8 biotech NA drugbank , DGIDB Lymphoma[MeSHID:D008223]
Ki-1+ Anaplastic Large Cell Lymphoma[MeSHID:D017728]
Hodgkin Disease[MeSHID:D006689]
Disruptive
Impulse Control
and Conduct Disorders[MeSHID:D007174]
0.71 approved,investigational binder,inhibitor
brentuximab vedotin tumor necrosis factor receptor superfamily member 8 biotech NA drugbank , DGIDB Lymphoma[MeSHID:D008223]
Ki-1+ Anaplastic Large Cell Lymphoma[MeSHID:D017728]
Hodgkin Disease[MeSHID:D006689]
Disruptive
Impulse Control
and Conduct Disorders[MeSHID:D007174]
NA approved,investigational binder
brentuximab vedotin lymphocyte activation antigen cd30 NA Successful target TTD , DGIDB Lymphoma[MeSHID:D008223]
Ki-1+ Anaplastic Large Cell Lymphoma[MeSHID:D017728]
Hodgkin Disease[MeSHID:D006689]
Disruptive
Impulse Control
and Conduct Disorders[MeSHID:D007174]
0.71 approved inhibitor
brentuximab vedotin lymphocyte activation antigen cd30 NA Successful target TTD , DGIDB Lymphoma[MeSHID:D008223]
Ki-1+ Anaplastic Large Cell Lymphoma[MeSHID:D017728]
Hodgkin Disease[MeSHID:D006689]
Disruptive
Impulse Control
and Conduct Disorders[MeSHID:D007174]
NA approved antibody
brentuximab vedotin lymphocyte activation antigen cd30 NA Successful target TTD , DGIDB Lymphoma[MeSHID:D008223]
Ki-1+ Anaplastic Large Cell Lymphoma[MeSHID:D017728]
Hodgkin Disease[MeSHID:D006689]
Disruptive
Impulse Control
and Conduct Disorders[MeSHID:D007174]
NA approved unknown
click here to return to the previous page